Amphastar subsidiary enters contract manufacturing deal with related party Hanxin for Chinese market

Amphastar Pharmaceuticals, Inc.

ANP will manufacture APIs and finished products on cost-plus basis for Hanxin, which will file for Chinese marketing authorizations.
Hanxin, majority-owned by Drs. Zhang, Luo and family, is a related party; deal approved by independent disinterested directors.
Hanxin commits to minimum purchase quantities under the agreement dated April 19, 2022; material terms to be filed with Q2 2022 10-Q.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.